Sanofi touts Acomplia for diabetes

Sanofi-Aventis has told a gathering of the American Diabetes Association that its blockbuster weight drug Acomplia helped overweight diabetics control blood sugar levels and lose weight. Twice as many patients taking Acomplia were able to manage levels of HbA1c compared to patients on a placebo. That's good news for Sanofi, which is touting Acomplia -- rimonabant -- as a drug that can treat a cluster of ailments. Analysts peg potential Acomplia sales at $1 billion per year. The study included people with type 2 diabetes.

- read this story from the International Herald Tribune for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.